DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde


Litton J, Rugo HS, Ettl J. et al.
EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced breast cancer and a germline BRCA mutation [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR.

Cancer Res 2018;
78: Abstr.. GS6-07

Download Bibliographical Data

Search in: